摘要
目的探索分析针对急性缺血性脑梗死患者予以先必新(依达拉奉右莰醇)联合阿替普酶静脉溶栓治疗的方法及其临床效果。方法将康美医院神经内科2021年1月-2022年12月期间收治的急性缺血性脑梗死患者60例纳入研究并随机分组,对照组30例均予以必存(依达拉奉)联合阿替普酶静脉溶栓治疗,研究组30例均予以先必新(依达拉奉右莰醇)联合阿替普酶静脉溶栓治疗。对比临床效果。结果研究组的治疗总有效率为96.67%,显著性超过对照组的73.33%(P<0.05)。研究组出血性转化率仅有6.67%,明显低于对照组的26.67%(P<0.05)。治疗前,两组患者的神经功能缺损NIHSS评分及神经功能恢复mRS评分均表现较高且不存在差异性(P>0.05),治疗后均获得明显降低(P<0.05),研究组更低(P<0.05)。两组治疗前超氧化物歧化酶(SOD)指标均较低、丙二醛(MDA)指标均较高且接近(P>0.05),治疗后均明显改善(P<0.05),研究组效果更为显著(P<0.05)。两组治疗前C反应蛋白(CRP)以及基质金属蛋白酶-9(MMP-9)水平均显著偏高且不具备差异性(P>0.05),治疗后均明显改善(P<0.05),研究组效果显著(P<0.05)。两组不良反应发生率均较低且接近(P>0.05)。结论针对急性缺血性脑梗死患者予以先必新联合阿替普酶静脉溶栓治疗,可以取得明显的临床效果,有助于尽快缓解机体氧化应激反应,改善神经功能缺损,减轻炎症反应,安全性高,值得推广应用。
Objective To explore and analyze the method and clinical effect of intravenous thrombolysis with prednisolone(edaravone dextranol)and ateplase for patients with acute ischemic cerebral infarction.Methods Sixty patients with acute ischemic cerebral infarction admitted to our hospital from January 2021 to December 2022 were included in the study and randomly divided into two groups.The control group(30 cases)received intravenous thrombolytic therapy with bisulfone(edaravone)and ateplase,while the study group(30 cases)received intravenous thrombolytic therapy with prednisone(edaravone dextranol)and ateplase.Compare clinical effects.Results The total effective rate in the study group was 96.67%,significantly higher than 73.33%in the control group(P<0.05).The hemorrhagic conversion rate in the study group was only 6.67%,significantly lower than 20.00%in the control group(P<0.05).Before treatment,the NIHSS score for neurological deficits and the mRS score for neurological recovery in the two groups were both high and close(P>0.05),and significantly decreased after treatment(P<0.05).The study group was significantly lower than the control group during the same period(P<0.05).Before treatment,the indicators of superoxide dismutase(SOD)were both lower and the indicators of malondialdehyde(MDA)were both higher and close to each other(P>0.05).After treatment,both groups were significantly improved(P<0.05),and the study group was significantly better than the control group(P<0.05).Before treatment,the levels of C-reactive protein(CRP)and matrix metalloproteinase-9(MMP-9)in both groups were significantly higher and close to each other(P>0.05).After treatment,both groups were significantly lower(P<0.05),compared with the control group(P<0.05).The incidence of adverse reactions in both groups was low and close(P>0.05).Conclusion For patients with acute ischemic cerebral infarction,intravenous thrombolytic therapy with Xianbixin combined with alteplase can achieve significant clinical results,help to alleviate the oxidative stress reaction of the body as soon as possible,improve neurological function defects,and alleviate inflammatory reactions.It is safe and worthy of wide application.
作者
邱凌骐
邱浩强
陈松深
Qiu Lingqi;Qiu Haoqiang;Chen Songshen(Department of Neurology,Kangmei Hospital,Puning,Guangdong 515300,China)
出处
《首都食品与医药》
2023年第16期47-50,共4页
Capital Food Medicine
基金
广东省揭阳市科技计划项目(编号:210714102350892)。
关键词
急性缺血性脑梗死
先必新
阿替普酶
静脉溶栓
Acute ischemic cerebral infarction
The first must be new
Ateplase
Intravenous thrombolysis
